RT Journal
A1 Alibhai SH, Yun L, Cheung AM, Paszat L
T1 SCreening for osteoporosis in men receiving androgen deprivation therapy
JF JAMA
JO JAMA
YR 2012
FD January 18
VO 307
IS 3
SP 255
OP 256
DO 10.1001/jama.2011.2022
UL http://dx.doi.org/10.1001/jama.2011.2022
AB 
To the Editor: Prostate cancer is the most common cancer in men.1 One in 2 men with prostate cancer is expected to receive androgen deprivation therapy (ADT). Use of ADT is associated with accelerated bone loss and an increased risk of fractures.2 To better characterize fracture risk and optimize bone health, a bone mineral density (BMD) test has been recommended prior to ADT initiation since 2006 in Canada3 and elsewhere.4 Low rates of BMD use have been reported by single centers.5 We examined the rate of BMD testing in men starting ADT in the province of Ontario, Canada, between 1995 and 2008.